MedTrace Logo

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution

NCT04664023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-06-23

No results posted yet for this study

Summary

Prospective study to describe the immunological, metabolic and serologic profile in the acute and post acute phases of Coronavirus disease (COVID-19)

Conditions

  • Covid19

Interventions

PROCEDURE

Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.

40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis

PROCEDURE

Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers

40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis

Sponsors & Collaborators

  • Poitiers University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2023-06-19
Completion
2023-06-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04664023 on ClinicalTrials.gov